Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Sawai, Kowa/Nissan Chemical Settle US Patent Suit over Livalo
February 3, 2017
- Nippon Shinyaku’s DMD Med Gets FDA’s Rare Pediatric Disease Designation
February 3, 2017
- Chugai to Optimize Area Management, Strengthen Expertise through Marketing System Reorganization: Marketing Chief
February 3, 2017
- Chugai to File Flurry of Applications in 2017 for New Drugs and Indications Including Emicizumab
February 3, 2017
- Chugai to Mull Authorized Biosimilars for 3 Key Cancer Meds on “Case-by-Case Basis”
February 2, 2017
- Takeda’s R&D Organization Rejig Making Steady Headway as a Whole
February 2, 2017
- New Firm for Nesp Biosimilar Will Broaden Options: Kyowa Kirin President
February 2, 2017
- EA Pharma Seeks Japan Approval of Constipation Med
February 2, 2017
- Chugai Logs Positive Sales in Japan, but Earnings Falter
February 2, 2017
- Gilead to Introduce Blister-Pack Harvoni by Early March
February 2, 2017
- Over 80% of 5-Year-Olds Eligible for Supplemental Dose of Pneumococcal Vaccine: Pfizer Survey
February 2, 2017
- Daiichi Sankyo Taps EVP Manabe as Next President
February 1, 2017
- KHK7580 Non-Inferior to Regpara in Japan Study: Kyowa Kirin
February 1, 2017
- Kyowa Kirin Sets Up New Firm for Nesp Authorized Biosimilar
February 1, 2017
- Daiichi Sankyo Sees High Odds of Success for CAR T-Cell Development: Exec
February 1, 2017
- Kyowa Kirin’s 2016 Sales, Profits Slip on Stronger Yen, Higher R&D Costs
February 1, 2017
- Kyowa Kirin, NCC to Collaborate on Cancer Meds, Biomarkers
February 1, 2017
- Takeda Obtains Japan Rights to Exelixis’ Cancer Drug
February 1, 2017
- Astellas Gets Rights to US Biotech’s Ruptured Eardrum Med
February 1, 2017
- Major Products Face Impending Listing of Generics, though Patents Remain for Some
February 1, 2017
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…